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Abstract 
Background: Knee osteoarthritis is a common disease associated with knee pain, physical disability, and joint 
stiffness. The use of non-surgical treatment methods in patients with knee osteoarthritis is important. 
Autologous conditioned serum (ACS) is a new regenerative therapeutic method that was investigated by a 
limited number of clinical trials. So far, using ACS in patients with Knee osteoarthritis remains to be 
controversial among physicians. Thus, the current study was carried out to compare the therapeutic effects of 
intra-articular ACS and ozone injections in patients with knee osteoarthritis. 
Materials and Methods: This prospective, double-blind randomized clinical trial was conducted among 60 
patients (30= interleukin-1 receptor antagonist (IL-1Ra) group, 30= ozone group) with knee osteoarthritis, who 
referred to the Pain Management Clinic of Akhtar Educational Hospital during 2018 to 2019. In the IL-1Ra 
group, 2 ml of IL-1Ra was injected into the knee joint. The regimen protocol consisted of 4 injections, 
performed on the first, seventh, fourteenth, and twenty-first days of the treatment and ozone group, 10 ml of 
ozone (30 μg/ml) + 5 ml of lidocaine 1% were injected into the knee joint. The regimen protocol consisted of 3 
injections, performed on the first day of the treatment, one month after the first injection, and two months after 
the first injection. The severity of pain was assessed by the patients’ self-report of pain and using the visual 
analog scale (VAS), before the treatment and 1, 3 and 6 months after the treatment. The Knee Injury and 
Osteoarthritis Outcome Score (KOOS) and the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) questionnaires were also measured at before and 6 months following treatment. 
Results: The changes in the VAS pain at different time periods showed statistically significant differences in 
the two groups, (P=0.0001). There was no significant difference between the two groups before the treatment 
and one month and three months after the initiation of the treatment; however, there was a significant 
difference between the two groups six months after the initiation of the treatment (P=0.0001). KOOS scores 
of symptoms, daily activities, and athletic and recreational functions were significantly higher in the IL-1Ra 
group, and the WOMAC scores of physical function and joint stiffness and the overall scores were 
significantly higher in the IL-1Ra group, (p<0.05). 
Conclusion: The intra-articular injection of IL-1Ra is a low-invasive, safe, effective, and long-acting method. 
In patients with knee osteoarthritis, clinical improvements and responses to the intra-articular IL-1Ra injection 
are better and longer compared to ozone injection. Therefore, it can be considered as a suitable choice in 
treating patients with chronic knee pain.  
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Introduction 
Knee osteoarthritis is a common disease associated 
with tissue inflammation, physical disability, and 
cartilage hemostasis imbalance. Almost 25% of 
people over 50 years of age experience knee pain, 
joint stiffness, and reduced function caused by knee 
osteoarthritis1. Currently, various surgical treatments 
are used to treat knee osteoarthritis2,3. By performing 
surgery the cartilage parts, mechanical stimulations, 
inflammatory cells, and other factors can be removed 
from the knee joint; however, it cannot result in 
restoring the joint or repairing knee osteoarthritis. In 
the last decade, many physicians have used ozone 
injections in the treatment of knee osteoarthritis. 
Ozone is a highly oxidative dissolved gas that 
enhances the nociceptive effects by applying a 
variety of mechanisms4. In many studies, the effect 
and safety of ozone therapy have been shown in the 
treatment of knee osteoarthritis and other 
musculoskeletal diseases5-11. Nowadays, injecting 
ozone is applied to treat knee osteoarthritis in 
orthopedic centers in Europe12-14. However, in recent 
studies conducted to examine osteoarthritis, the role 
of biochemical processes in the pathology of the 
disease and the development of new and regenerative 
therapies has attracted many researchers’ and 
physicians’ attention. 
One of the mechanisms of the progression of knee 
osteoarthritis is the degenerative control pathway of 
the disease caused due to the pathological increase in 
inflammation of cytokines and catabolic factors in 
and around the synovial space. Inflammatory and 
catabolic proteins, such as interleukin-1 beta, tumor 
necrosis factor-α, and metalloproteinase matrix, play 
roles in the cartilage destruction and the progression 
of osteoarthritis.15The approaches that block these 
changes not only can improve the symptoms of the 
disease but also can stop or reverse the disease 
progression. 
Anti-inflammatory cytokines in the blood are 
interleukin-1 receptor antagonist, soluble interleukin-
1 receptor type I, soluble tumor necrosis factor 
receptor-type I, and soluble tumor necrosis factor 
receptor type II16. 
New therapeutic approaches attempt to produce anti-
inflammatory and anabolic proteins at high 
concentrations by overcoming the high pathological 
levels of pro-inflammatory and catabolic proteins that 
cause osteoarthritis. 
Autologous conditioned serum (ACS) is a complete 
autologous blood product used to treat joint 
osteoarthritis, spinal radiculopathy, tendon and muscle 
damage17. 
ACS is a non-cellular treatment that has significant 
biochemical and clinical differences with PRP and 
other autologous blood substitution treatments18. 
ACS is achieved by venous blood incubations at the 
physiological temperature (about 37C) for 6-9 hours 
in a special syringe. ACS produces products of anti-
inflammatory cytokines, such as interleukin-1 receptor 
antagonist17, which are important mediators of 
inflammation and tissue destruction in musculoskeletal 
diseases19. ACS containing this cytokine is extracted 
from the coagulated blood by centrifugation and is 
injected into the affected tissue using a sterile filter. In 
randomized clinical trials, the effect of ACS on the 
treatment of knee and hip osteoarthritis20-22, lumbar 
radicular compression23, and muscle damage24 have 
been shown. 
The experimental model of osteoarthritis in the in vivo 
environment demonstrated that the interleukin-1 
receptor antagonist gene (IL-1Ra) significantly 
improved the clinical parameters of pain, patient 
activity, maintenance of articular cartilage, and 
beneficial effects on the histological parameters of the 
synovial membranes and adjoining articular 
cartilage25. 
Animal studies have indicated promising results as 
well. In a placebo-controlled study carried out on a 
horse suffered from tendinopathy, an ACS injection 
was performed and a significant reduction was 
observed in the horse’s lameness within 10 days26. 
Clinical trials have revealed that injecting ACS 
improved pain and joint function and delayed the need 
for surgery in patients21,27,28. 
ACS is a new regenerative therapeutic method that 
was investigated by a limited number of clinical trials. 
Therefore, this study was conducted on the Iranian 
population due to the high prevalence of knee 
osteoarthritis in this population, the presence of 
contradictory views on whether applying ACS can 
improve clinical outcomes and the high costs of this 
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treatment. 
Methods 
This prospective, double-blind randomized clinical 
trial was carried out on patients with knee 
osteoarthritis referred to pain Management Clinic of 
Shohaday-e-Tajrish and Akhtar Hospitals in 2018-
2019. Patients who had given their full informed 
consent, were 40 years old and older, suffered from 
knee osteoarthritis pain for more than three months, 
and the radiographic results confirmed the knee 
osteoarthritis based on the criteria of American 
College of Rheumatology (ACR)29 were included. 
Patients who had not given their consent for taking 
part in this study, had a history of knee surgery, 
deformity, lower limb contraction, lower limb 
neurovascular disease, acute lumbar pathology, 
injection of steroid drugs in the last two months, 
inflammatory rheumatoid arthritis, infection, 
diabetes, pregnancy, and breastfeeding, those who 
had a BMI>35, were candidates for knee surgery, 
suffered from knee deviation (varus or valgus more 
than 5 degrees) confirmed by a three joint view 
graph, had radicular knee pain, took anticoagulant 
drugs, suffered from post-traumatic arthritis, had a 
history of intra-articular injection or ozone therapy in 
the past 12 months, were sensitive to any of the drugs 
used in this study, suffered from a systemic or 
psychiatric disease, had severe osteoarthritis (over 
stage 3), had an intra-articular hyaluronic acid 
injection in the past 12 months, suffered from 
hepatitis, HIV, cytomegalovirus, syphilis, and 
osteomyelitis or abused substances and alcohol were 
excluded. 
Patients were randomly assigned to treatment groups 
according to the random numbers table: 
I) 2 ml of IL-1RA. 
II) 10 ml of ozone (30 μg/ml) + 5 ml of 
lidocaine 1%. 
In the first group, to prepare the IL-1RA, 50 ml of 
venous blood was taken from the patients using a 
special syringe (manufactured in Germany by 
Orthokine) containing glass beads coated with 
CrSO4. Then, to ensure complete mixing and 
maximum contact between the beads and blood, the 
syringe was rotated slowly and was immediately 
stored in a special incubator at 37°C and transferred 
to a laboratory in 24 hours. In the laboratory, the blood 
samples were tested for hepatitis A and B and HIV. If 
any of the tests were positive, the patients were again 
tested with new blood samples. If any of the 
mentioned tests were again positive, the patient would 
be excluded from the study. In the case of tests being 
negative, the non-cellular product (IL-1RA) was 
prepared by the laboratory and was returned to the 
hospital in 2 ml vials at -20°C in 14-20 days. The 
regimen protocol consisted of four injections, 
performed on the first, seventh, fourteenth, and 
twenty-first days of the treatment. 
In the second group, 10 ml of ozone (30 μg/ml) + 5 ml 
of lidocaine 1% were injected into the knee joint. This 
group underwent three injections, i.e. on the first day 
of the treatment, one month after the first injection, 
and two months after the first injection. 
To conduct the procedure, the patient was placed in a 
supine position and the landmark of the injection area 
was determined using a knee flexion of about 30 to 45 
degrees on the lateral side of the knee. Afterward, the 
injection site was disinfected with povidone-iodine 
solution and 2 ml of lidocaine 2% was injected to the 
skin and articular surface for numbness using a 27-
gauge needle. After aspiration and ensuring the correct 
positioning of the needle by ultrasound guidance 
(Sono Site, PICO.probe Convex 3-7, Linear 5-12), the 
intra-articular injection of IL-1RA or ozone was 
performed using the same needle. 
Five items, including pain, symptoms, daily activities, 
athletic and recreational functions, and knee-related 
quality of life, were measured by the Knee Injury and 
Osteoarthritis Outcome Score (KOOS)29, which is a 4-
point Likert-type scale (0-4), and 3 items, including 
pain, stiffness, and physical function, were measured 
by the Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC)30, which is a 5-point 
Likert-type scale (0-5), completed by the patients 
before the initiation of the treatment and six months 
after the last injection. The level of pain was evaluated 
by the VAS (0-10), based on which the patients were 
required to determine their pain levels by rating their 
pain levels before the initiation of the treatment, one 
month after the initiation of the treatment, and three 
months after the last injection. In the case of 
complication, the type of complication was also 
recorded. 
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It should also be noted that during the study period, 
the patients did not take steroids, antidepressants and 
sedative medications. 
In the case of pain with a score of more than 3 during 
the study, they could take acetaminophen (up to 4 
grams per day). 
The obtained information was then coded and 
entered into SPSS version 19. In the traditional 
orthopedics, 100 was considered as no problem and 0 
was regarded as the worst state. To comply with this 
standard, the subscales’ scores were calculated by 
dividing the overall score of each subscale by the 
maximum possible score of the normalized subscale. 
After examining the normal distribution of 
quantitative data by the Kolmogorov-Smirnov test, 
the quantitative variables were compared using the t-
test, Mann-Whitney test, and repeated measurement 
ANOVA, and paired t-test and the qualitative 
variables were examined using the Chi-square test. 
P<0.05 was considered statistically significant. 
Results 
The results of comparing the demographic 
information of the patients in the two groups are 
presented in Table 1. 
Comparing the changes in the pain levels examined 
by the VAS before the initiation of the treatment and 
one month, three months, and six months after the 
initiation of the treatment in the two groups showed 
that there were statistically significant differences 
between the two groups in terms of the changes in 
the pain scores (P = 0.0001). 
The results of comparing the pain levels at different 
times are presented in Table 2 and show that there 
was no significant difference between the two groups 
before the treatment and one month and three months 
after the initiation of the treatment; however, there 
was a significant difference between the two groups 
six months after the initiation of the treatment 
(P=0.0001). 
The results of comparing the KOOS scores before the 
start of the treatment in the two groups are presented 
in Table 3 and show that there were significant 
differences between the two groups in terms of the 
scores of pain, symptoms, daily activities, and athletic 
and recreational functions. 
The results of comparing the KOOS scores obtained 
six months after the initiation of the treatment by the 
two groups are presented in Table 4 and indicate that 
the scores of symptoms, daily activities, and athletic 
and recreational functions were significantly higher in 
the IL-1Ra group compared to the other group. 
The results of comparing the WOMAC scores 
obtained before the initiation of the treatment between 
the two groups are presented in Table 5 and 
demonstrate no significant differences between the 
two groups. 
The results of comparing the WOMAC scores obtained 
six months after the initiation of the treatment between 
the two groups are presented in Table 6. The scores of 
physical function and joint stiffness and the overall 
scores were significantly higher in the IL-1Ra group 
compared to the other group; however, the scores of pain 
were not significantly different between the two groups. 
There were statistically significant differences in terms of 
changes in the pain levels in each group at different 
times, i.e., before the injection, and during the six months 
follow up (P= 0.0001). 
The changes in each of the KOOS and WOMAC scores 
in each group were statistically significant before the 
initiation of the treatment and six months after the last 
injection (P= 0.0001). None of the patients reported any 
complications related to the procedure. 
Table 1: The comparison of the demographic information between the two groups. 





0.006 51.5±5.4 56.8±8.6 Age  (yr.) 
0.214 30.5±2.6 31.1±3.4 BMI (kg/m2) 
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Discussion 
In this study, the effect of intra-articular injection of 
IL-1Ra was compared with ozone as a control group. 
In the present study, the changes in the pain VAS at 
different times and comparing such changes between 
the two groups showed a significant decrease in the 
pain VAS in the IL-1Ra group. 
There was a significant decrease in the pain VAS in 
the IL-1Ra group six months after the initiation of the 
treatment. 
Furthermore, six months after the initiation of the 
treatment, the KOOS pain scores were higher in the 
 
Figure 1. The comparison of the changes in the pain levels between the two groups at different times (P=0.0001). 
 
Table 2: The comparison of the pain levels between the two groups at different times. 





0.215 6.03±0.9 5.8±0.6     VAS before injection              
0.171 3.5±0.6 3.7±0.5 VAS 1 month after injection 
0.059 3.2±0.6 2.9±0.5 VAS 3 months after injection 
0.0001 4.3±0.5 2.5±0.6 VAS 6 months after injection 
 
 Table 3: The comparison of the KOOS scores before the initiation of the treatment between the two groups. 





0.035 40.8±12.9 47.2±9.1     Pain              
0.012 47.7±9.1 41.2±9.5 symptoms 
0.0001 37.8±9.0 52.2±7.6 daily activities 
0.0001 22.3±7.5 30.4±11.8 athletic and recreational functions. 
 
0.124 23.3±11.1 27.4±11.8 Quality of Life 
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IL-1Ra group and the pain levels showed a higher 
reduction in this group compared to the other group; 
however, these changes were not significantly 
different compared to the ozone group. The KOOS 
scores of symptoms, daily activities, and athletic and 
recreational functions obtained by the IL-1Ra group 
demonstrated a significant improvement. The KOOS 
scores of knee-related quality of life did not indicate 
any significant differences between the two groups. 
Additionally, the joint stiffness scores and the 
WOMAC scores of physical activity, and the overall 
score of WOMAC were higher in the IL-1Ra group 
compared to the other group and the patients 
assigned to this group showed a better improvement 
compared to the ozone group. The comparison of the 
two groups was statistically significant. The WOMAC 
pain scores were higher in the IL-1Ra group; however, 
this difference was not significant between the two 
groups. 
The findings of the current study are consistent with 
other studies. In a meta-analysis conducted based on 
scientific evidence, it was revealed that the injection of 
ozone to patients with knee osteoarthritis improved 
mild to moderate pain in the short term (1-3 months)31. 
Moreover, RCT studies indicated that the short-term 
effect of ozone injection on pain relief was better than 
the placebo31 and corticosteroids14. This is while the 
short-term effect of ozone injection on the recovery of 
pain was similar to dextrose32 and hyaluronic acid33-36. 
The therapeutic effect of ozone had reduced 3-6 
Table 5: The comparison of the WOMAC scores obtained before the initiation of the treatment in the two groups. 





0.313 42.0±12.3 45.7±15.8 Pain              
0.083 40.3±11.9 45.2±9.6 Stiffness 
0.155 40.6±8.1 45.0±14.8 Physical function 
0.113 122.9±25.6 135.9±36.3 Overall score 
 
 Table 6: The comparison of the WOMAC scores obtained six months after the initiations of the treatment between 
the two groups. 





0.178 68.1±9.1 71.4±9.9  Pain              
0.028 56.2±9.6 61.6±8.8 Stiffness 
0.034 67.3±11.4 73.3±10.3 Physical function 
0.024 191.5±25.1 206.3±24.4 Overall score 
 
 
Table 4: The comparison of the KOOS scores obtained six months after the initiation of the treatment between the 
two groups. 





0.212 70.9±8.4 73.7±8.7 Pain              
0.002 63.1±8.0 72.6±13.9 symptoms 
0.0001 59.1±9.4 73.1±8.6 daily activities 
0.019 46.7±7.9 53.2±13.0 athletic and recreational functions. 
 
0.882 46.9±11.4 46.0±10.4 Quality of Life 
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months after the injection, and its therapeutic effect 
was gradually lower than the mentioned injections31. 
This is in line with the results obtained in the present 
study. 
Another study that compared the effects of ozone 
with hyaluronic acid stated that while the therapeutic 
effect of ozone injection had significantly reduced 
after three months, the therapeutic effect of 
hyaluronic acid had continued six months after the 
injection. This is while the therapeutic effect of 
ozone therapy disappeared six months after the 
injection34.  
It seems that ACS/IL-1Ra has a longer biological 
beneficial effect on the improvement of clinical 
symptoms associated with osteoarthritis. 
In another study, which compared the effect of 
hyaluronic acid and autologous conditioned serum, 
after 104 weeks of follow-up, the symptom and 
clinical improvements of knee osteoarthritis were 
significantly higher in the autologous conditioned 
serum group compared to the hyaluronic acidgroup37. 
In contrast, in some other studies, there were not any 
significant differences with regard to the 
improvement in joint function and the reduction of 
knee osteoarthritis pain in the two groups of ozone 
and hyaluronic acid during the six months of follow 
up and none of them was superior to the other one35.  
Furthermore, the WOMAC subscales of joint 
stiffness and physical function and the KOOS 
subscales of symptoms, daily activities, and athletic 
and recreational functions indicated significant 
improvements in the IL-1Ra group six months after 
the initiation of the treatment; however, the 
WOMAC and KOOS subscales of pain were not 
significantly different between the two groups six 
months after the start of the treatment. It seems that 
while ozone still had a significant effect on pain 
relief six months later, it did not improve the function 
of the knee joint. This finding is also consistent with 
other studies32.  
Pre-inflammatory cytokines, such as IL-1β and tumor 
necrosis factor, are known as mediators of the 
osteoarthritis process that provide the possibility of 
achieving therapeutic goals. In a few studies, the 
blocking effect of these mediators has been studied. 
Several studies have also shown the role of these 
mediators in disease progression38.  Accordingly, 
because of the role IL-1β in the pathogenesis of 
osteoarthritis, its antagonistic choice seems logical in 
treating these patients. 
The irreversible inflammatory cytokines may disrupt 
the cytokine homeostasis, which indicates the need for 
the treatment in the early stages of the disease. 
However, due to the complexity of the pathogenesis of 
osteoarthritis, a general strategy for treating these 
patients cannot be considered39,40. 
Some clinical trial studies demonstrated that ACS in 
the knee osteoarthritis was the last stage of treatment 
and when no improvements were observed in the 
patient’s used knee arthroplasty. 
Serum autologous, which induces the synthesis of anti-
inflammatory cytokines, appears to be effective in the 
symptomatic treatment of knee osteoarthritis. 
Therefore, the results of applying IL-1Ra produced on 
the basis of human serum may be different in various 
people. 
Among the limitations of this study, the differences in 
human serum and molecular profile of the patients that 
may cause differences in the quality of IL-1Ra, 
differences in the ozone injection protocol, 
psychosocial and economic factors, anthropometrics, 
recommended sports programs, which have a 
significant impact on the results and the durability of 
the effects of the treatment, can be mentioned. 
It seems that this ACS is associated with beneficial 
biological effects in patients with knee osteoarthritis. 
Conclusion 
The intra-articular injection of IL-1Ra is a low-
invasive, safe, effective, and long-acting method. In 
patients with knee osteoarthritis, clinical 
improvements and responses to the intra-articular IL-
1Ra injection are better and longer compared to ozone 
injection. Therefore, it can be considered as a suitable 
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